
AstraZeneca Commits $50B to U.S. Expansion Amid Trump Tariff Push
Jul 22, 2025 01:18 am UTC| Health Business
AstraZeneca (NASDAQ: AZN) has unveiled plans to invest $50 billion in U.S. manufacturing and RD infrastructure by 2030, marking one of the largest expansions in the pharmaceutical industry. The move responds to renewed...

FDA Panel Rejects Otsuka’s PTSD Drug Combo with Zoloft
Jul 19, 2025 02:42 am UTC| Governance Health
A U.S. Food and Drug Administration (FDA) advisory panel has voted overwhelmingly against the approval of Otsuka Pharmaceuticals antipsychotic drug, brexpiprazole (Rexulti), in combination with Viatris antidepressant...

Trump Pushes China for Death Penalty on Fentanyl Traffickers Amid Drug Crisis
Jul 17, 2025 01:02 am UTC| Politics Governance Health
U.S. President Donald Trump expressed confidence on Wednesday that China will soon impose the death penalty for fentanyl manufacturing and trafficking, signaling renewed optimism for a bilateral crackdown on the opioid...

U.S. Drops Charges Against Utah Doctor in COVID-19 Vaccine Case Amid Political Uproar
Jul 12, 2025 22:26 pm UTC| Politics Law Health
U.S. Attorney General Pam Bondi has dropped the federal case against Utah doctor Michael Kirk Moore Jr., who was accused of issuing fake COVID-19 vaccine certificates and discarding over $28,000 worth of...

FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies
Jun 28, 2025 03:38 am UTC| Health Governance Science
The U.S. Food and Drug Administration (FDA) has removed the Risk Evaluation and Mitigation Strategies (REMS) requirement for all currently approved CAR-T cell therapies, a move expected to improve patient access to these...

China Cracks Down on Fentanyl Precursors Amid U.S. Trade Pressure
Jun 26, 2025 05:53 am UTC| Politics Health
China has taken notable steps in recent days to tighten control over fentanyl precursors, signaling possible cooperation with U.S. demands amid ongoing trade tensions. The move comes after months of deadlock and could pave...

Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
Jun 26, 2025 01:48 am UTC| Business Health Science
Shares of Neuren Pharmaceuticals Ltd (ASX:NEU) jumped over 10% on Thursday after the company announced a key development in its rare disease pipeline. The U.S. Patent and Trademark Office has approved Neurens patent...